Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation

Bone

Volumn 40, Issue 4, 2007, Pages 867-875

  Bakiri, Latifa ^a,b   Takada, Yasunari ^c   Radolf, Martin ^a   Eferl, Robert ^a,d   Yaniv, Moshe ^b   Wagner, Erwin F ^a   Matsuo, Koichi ^a,c  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^b INSTITUT PASTEUR   (France)

^c KEIO UNIVERSITY   (Japan)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

AP 1; c Fos; Dimer; Fra 1; Jun; NFAT; Osteoclast; Rescue; Transcription

Indexed keywords

DIMER; MUTANT PROTEIN; PROTEIN C FOS; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CONTROLLED STUDY; DIMERIZATION; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; TRANSACTIVATION;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; DIMERIZATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; OSTEOCLASTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FOS; TRANSCRIPTION FACTOR AP-1;

EID: 33847738172     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.11.005     Document Type: Article

References (45)

1. Ameyar-Zazoua M., Wisniewska M.B., Bakiri L., Wagner E.F., Yaniv M., and Weitzman J.B. AP-1 dimers regulate transcription of the p14/p19ARF tumor suppressor gene. Oncogene 24 (2005) 2298-2306
2. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202 (2005) 1261-1269
3. Bakiri L., Lallemand D., Bossy-Wetzel E., and Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 19 (2000) 2056-2068
4. Bakiri L., Matsuo K., Wisniewska M., Wagner E.F., and Yaniv M. Promoter specificity and biological activity of tethered AP-1 dimers. Mol. Cell. Biol. 22 (2002) 4952-4964
5. Behrens A., Sibilia M., and Wagner E.F. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat. Genet. 21 (1999) 326-329
6. Bergers G., Graninger P., Braselmann S., Wrighton C., and Busslinger M. Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. Mol. Cell. Biol. 15 (1995) 3748-3758
7. Blanar M.A., and Rutter W.J. Interaction cloning: identification of a helix-loop-helix zipper protein that interacts with c-Fos. Science 256 (1992) 1014-1018
8. Brown P.H., Chen T.K., and Birrer M.J. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 9 (1994) 791-799
9. Chinenov Y., and Kerppola T.K. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 20 (2001) 2438-2452
10. Clausen B.E., Burkhardt C., Reith W., Renkawitz R., and Förster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8 (1999) 265-277
11. David J.P., Sabapathy K., Hoffmann O., Idarraga M.H., and Wagner E.F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell. Sci. 115 (2002) 4317-4325
12. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13 (1999) 2412-2424
13. Eferl R., Hoebertz A., Schilling A.F., Rath M., Karreth F., Kenner L., et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J. 23 (2004) 2789-2799
14. Eferl R., and Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev., Cancer 3 (2003) 859-868
15. Fleischmann A., Hafezi F., Elliott C., Reme C.E., Ruther U., and Wagner E.F. Fra-1 replaces c-Fos-dependent functions in mice. Genes Dev. 14 (2000) 2695-2700
16. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., et al. Requirement for NF-kB in osteoclast and B-cell development. Genes Dev. 11 (1997) 3482-3496
17. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266 (1994) 443-448
18. Ikeda F., Nishimura R., Matsubara T., Tanaka S., Inoue J., Reddy S.V., et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114 (2004) 475-484
19. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., and Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3 (1997) 1285-1289
20. Kataoka K., Fujiwara K.T., Noda M., and Nishizawa M. MafB, a new Maf family transcription activator that can associate with Maf and Fos but not with Jun. Mol. Cell. Biol. 14 (1994) 7581-7591
21. Kataoka K., Igarashi K., Itoh K., Fujiwara K.T., Noda M., Yamamoto M., et al. Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor. Mol. Cell. Biol. 15 (1995) 2180-2190
22. Kawaida R., Ohtsuka T., Okutsu J., Takahashi T., Kadono Y., Oda H., et al. Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. J. Exp. Med. 197 (2003) 1029-1035
23. Kenner L., Hoebertz A., Beil T., Keon N., Karreth F., Eferl R., et al. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J. Cell Biol. 164 (2004) 613-623
24. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
25. Lallemand D., Ham J., Garbay S., Bakiri L., Traincard F., Jeannequin O., et al. Stress-activated protein kinases are negatively regulated by cell density. EMBO J. 17 (1998) 5615-5626
26. Lallemand D., Spyrou G., Yaniv M., and Pfarr C.M. Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts. Oncogene 14 (1997) 819-830
27. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1566-1571
28. Lomaga M.A., Yeh W.C., Sarosi I., Duncan G.S., Furlonger C., Ho A., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13 (1999) 1015-1024
29. Maruyama K., Takada Y., Ray N., Kishimoto Y., Penninger J.M., Yasuda H., et al. Receptor activator of NF-κB ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J. Immunol. 177 (2006) 3799-3805
30. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279 (2004) 26475-26480
31. Matsuo K., Owens J.M., Tonko M., Elliott C., Chambers T.J., and Wagner E.F. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24 (2000) 184-187
32. Morgenstern J.P., and Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18 (1990) 3587-3596
33. Naito A., Azuma S., Tanaka S., Miyazaki T., Takaki S., Takatsu K., et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4 (1999) 353-362
34. Nicklin M.J., and Casari G. A single site mutation in a truncated Fos protein allows it to interact with the TRE in vitro. Oncogene 6 (1991) 173-179
35. Nishiwaki T., Yamaguchi T., Zhao C., Amano H., Kurt D.H., Bornstein P., et al. Reduced expression of thrombospondins and craniofacial dysmorphism in mice overexpressing Fra1. J. Bone Miner. Res. 21 (2006) 596-604
36. O'Shea E.K., Rutkowski R., and Kim P.S. Mechanism of specificity in the Fos-Jun oncoprotein heterodimer. Cell 68 (1992) 699-708
37. Pognonec P., Boulukos K.E., Aperlo C., Fujimoto M., Ariga H., Nomoto A., et al. Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity. Oncogene 14 (1997) 2091-2098
38. Pratt M.A., Kralova J., and McBurney M.W. A dominant negative mutation of the alpha retinoic acid receptor gene in a retinoic acid-nonresponsive embryonal carcinoma cell. Mol. Cell. Biol. 10 (1990) 6445-6453
39. Sato M., Morii E., Takebayashi-Suzuki K., Yasui N., Ochi T., Kitamura Y., et al. Microphthalmia-associated transcription factor interacts with PU.1 and c-Fos: determination of their subcellular localization. Biochem. Biophys. Res. Commun. 254 (1999) 384-387
40. Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 416 (2002) 744-749
41. Thepot D., Weitzman J.B., Barra J., Segretain D., Stinnakre M.G., Babinet C., et al. Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. Development 127 (2000) 143-153
42. Wagner E.F., and Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol. Rev. 208 (2005) 126-140
43. Wang Z.Q., Ovitt C., Grigoriadis A.E., Möhle-Steinlein U., Rüther U., and Wagner E.F. Bone and haematopoietic defects in mice lacking c-fos. Nature 360 (1992) 741-744
44. Wrighton C., and Busslinger M. Direct transcriptional stimulation of the ornithine decarboxylase gene by Fos in PC12 cells but not in fibroblasts. Mol. Cell. Biol. 13 (1993) 4657-4669
45. Zhao C., Irie N., Takada Y., Shimoda K., Miyamoto T., Nishiwaki T., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 4 (2006) 111-121